Drug Discovery & Development | Teva Announces Additional Regulatory Exclusivity for TREANDA ... Business Wire (press release) TREANDA is indicated for the treatment of patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Important Safety Information. FDA grants Teva's Treanda orphan drug status Teva Gets Additional Exclusivity for Treanda Cancer drug Treanda gets orphan status, but that won't save Teva's shrinking ... |
